In This Article:
The gross proceeds to the company from the offering are expected to be approximately $5M, before deducting the placement agent’s fees and other offering expenses payable by the company. The company intends to use the net proceeds from this offering for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to the company’s technologies, licensing activities related to its current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital. H.C. Wainwright acted as sole book running manager for the offering.
Protect Your Portfolio Against Market Uncertainty
-
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
-
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KTTA:
Disclaimer & DisclosureReport an Issue
-
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004
-
Pasithea Therapeutics files to sell 3.25M shares of common stock, warrants
-
Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004
-
Pasithea Therapeutics to present updated data from Phase 1 trial of PAS-004
-
Morning Movers: Capri Holdings jumps following sale of Versace to Prada